Lantern Pharma Inc.

NASDAQ:LTRN

Biotechnology

Healthcare
$3.93 -4.67%

-$0.19 today

Market cap
$50.14M
Beta
2.32
P/E (TTM)
-2.7
EPS (TTM)
-$1.41
52W Low $1.11High $5.74

Volume 0.10M

Average 0.68M

LTRN Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Lantern Pharma Inc.NASDAQ: LTRN

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $3.85K fell 15.8% year over year, ahead of the -84.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 6.1% from the prior quarter. Over 3 fiscal years it compounded at +19.7% a year.

Context

  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -15.8% holds above the trailing-twelve-month pace of -84.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.85K-6.1% QoQ
Last fiscal yearDec 2025
$17.28K-90.9% YoY
LTMMar 2026
$16.56K-84.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.8%——
1 year-90.9%——
3-year CAGR+19.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
17.28K USD
Year-over-year change
-90.9%
4-year CAGR
+26.4%

Depreciation & Amortization vs competitors

How LTRN compares with its peers on the latest reported figures

  • LTRN's LTM Mar 2026 depreciation & amortization of $16.56K is the 2nd largest of the 5 companies compared; the peer median is $1K.
  • Its year-over-year change of -84.4% is the lowest of 3, against a peer median of +53.6%.
  • Over three fiscal years its annual growth of +19.7% compares with a peer median of -12.6%.
LTRN Competitors Peer median
Depreciation & Amortization for LTRN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$873K +7.1%+5.5%2.5%
LTRNLantern Pharma Inc.LTM Mar 2026$16.56K -84.4%+19.7%—
RNXTRenovoRx, Inc.LTM Mar 2026$2K +100.0%-30.7%0.1%
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$0 ———
ANVSAnnovis Bio, Inc.LTM Mar 2026$0 ———
Peer median (excluding LTRN) $1K+53.6%-12.6%1.3%

Competitors are the stored peer set for LTRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(12.36M)(14.26M)(15.96M)(20.78M)(17.12M)
Depreciation & Amortization6.76K10.08K14.62K190.49K17.28K
Deferred Income Tax00000
Stock-Based Compensation961.55K1.19M1.07M0650.88K
Change in Working Capital599.96K(611.86K)538.02K2.23M635.28K
Accounts Receivables000(175.72K)0
Inventory00000
Accounts Payables0001.64M0
Other Working Capital599.96K(611.86K)538.02K767.44K635.28K
Other Non-Cash Items203.22K906.49K(5.17K)549.36K139.02K
Operating Cash Flow(10.59M)(12.77M)(14.35M)(17.81M)(15.68M)
Capital Expenditures(15.5K)(27.84K)(18.73K)(12.6K)(1.72K)
Acquisitions (Net)00000
Purchases of Investments(19.58M)(3.91M)(8.2M)(17.28M)(14.72M)
Sales of Investments64.09K4.12M7.28M20.66M25.78M
Other Investing Activities00000
Investing Cash Flow(19.53M)179.27K(930.21K)3.37M11.06M
Debt Repayment00000
Common Stock Issued69M0066.71K1.64M
Common Stock Repurchased0(2.48M)(500K)00
Dividends Paid00000
Other Financing Activities(4.64M)2.78M00(139.75K)
Financing Cash Flow63.42M(2.18M)(500K)66.71K1.5M
Effect of Forex Changes1.07K(10.61K)(28.46K)(49.55K)33.43K
Net Change in Cash33.3M(14.78M)(15.81M)(14.43M)(3.09M)
Free Cash Flow(10.61M)(12.8M)(14.37M)(17.83M)(15.68M)

Lantern Pharma Inc.

NASDAQ:LTRN

Intrinsic Alpha fair value

Locked

Current Price

$3.93

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.